115 related articles for article (PubMed ID: 25165849)
1. The Cape Chacma baboon is not suitable for evaluating human targeted anti-GPVI agents.
Janse van Rensburg WJ; Badenhorst PN; Roodt JP
Platelets; 2015; 26(6):552-7. PubMed ID: 25165849
[TBL] [Abstract][Full Text] [Related]
2. Comparison of common platelet receptors between the chacma baboon (Papio ursinus) and human for use in pre-clinical human-targeted anti-platelet studies.
Janse van Rensburg WJ
Platelets; 2016 Jun; 27(4):322-32. PubMed ID: 26559117
[TBL] [Abstract][Full Text] [Related]
3. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding.
Al-Tamimi M; Mu FT; Arthur JF; Shen Y; Moroi M; Berndt MC; Andrews RK; Gardiner EE
Platelets; 2009 Mar; 20(2):75-82. PubMed ID: 19235048
[TBL] [Abstract][Full Text] [Related]
4. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
5. Study of a humanized inhibitory anti-platelet glycoprotein VI phage antibody from a phage antibody library.
Liu Q; Zhang C; Yu L; Shi Y; Zhang L; Peng J; Ji X; Hou M
Hematology; 2016 Jan; 21(1):60-7. PubMed ID: 26330203
[TBL] [Abstract][Full Text] [Related]
6. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents.
Boylan B; Berndt MC; Kahn ML; Newman PJ
Blood; 2006 Aug; 108(3):908-14. PubMed ID: 16569773
[TBL] [Abstract][Full Text] [Related]
7. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.
Massberg S; Konrad I; Bültmann A; Schulz C; Münch G; Peluso M; Lorenz M; Schneider S; Besta F; Müller I; Hu B; Langer H; Kremmer E; Rudelius M; Heinzmann U; Ungerer M; Gawaz M
FASEB J; 2004 Feb; 18(2):397-9. PubMed ID: 14656994
[TBL] [Abstract][Full Text] [Related]
8. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats.
Li H; Lockyer S; Concepcion A; Gong X; Takizawa H; Guertin M; Matsumoto Y; Kambayashi J; Tandon NN; Liu Y
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1199-205. PubMed ID: 17322098
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the GPVI inhibitors losartan and honokiol.
Onselaer MB; Nagy M; Pallini C; Pike JA; Perrella G; Quintanilla LG; Eble JA; Poulter NS; Heemskerk JWM; Watson SP
Platelets; 2020; 31(2):187-197. PubMed ID: 30849265
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen.
Nieswandt B; Brakebusch C; Bergmeier W; Schulte V; Bouvard D; Mokhtari-Nejad R; Lindhout T; Heemskerk JW; Zirngibl H; Fässler R
EMBO J; 2001 May; 20(9):2120-30. PubMed ID: 11331578
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity.
Loyau S; Dumont B; Ollivier V; Boulaftali Y; Feldman L; Ajzenberg N; Jandrot-Perrus M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):778-85. PubMed ID: 22155453
[TBL] [Abstract][Full Text] [Related]
12. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice.
Grüner S; Prostredna M; Koch M; Miura Y; Schulte V; Jung SM; Moroi M; Nieswandt B
Blood; 2005 Feb; 105(4):1492-9. PubMed ID: 15507524
[TBL] [Abstract][Full Text] [Related]
13. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents.
Mangin PH; Tang C; Bourdon C; Loyau S; Freund M; Hechler B; Gachet C; Jandrot-Perrus M
J Pharmacol Exp Ther; 2012 Apr; 341(1):156-63. PubMed ID: 22238212
[TBL] [Abstract][Full Text] [Related]
14. A new monoclonal antibody, mAb 204-11, that influences the binding of platelet GPVI to fibrous collagen.
Moroi M; Mizuguchi J; Kawashima S; Nagamatsu M; Miura Y; Nakagaki T; Ito K; Jung SM
Thromb Haemost; 2003 Jun; 89(6):996-1003. PubMed ID: 12783112
[TBL] [Abstract][Full Text] [Related]
15. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization.
Matsumoto Y; Takizawa H; Gong X; Le S; Lockyer S; Okuyama K; Tanaka M; Yoshitake M; Tandon NN; Kambayashi J
Thromb Res; 2007; 119(3):319-29. PubMed ID: 16566959
[TBL] [Abstract][Full Text] [Related]
16. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo.
Schulz C; Penz S; Hoffmann C; Langer H; Gillitzer A; Schneider S; Brandl R; Seidl S; Massberg S; Pichler B; Kremmer E; Stellos K; Schönberger T; Siess W; Gawaz M
Basic Res Cardiol; 2008 Jul; 103(4):356-67. PubMed ID: 18431526
[TBL] [Abstract][Full Text] [Related]
17. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
[TBL] [Abstract][Full Text] [Related]
18. Focusing on plasma glycoprotein VI.
Al-Tamimi M; Arthur JF; Gardiner E; Andrews RK
Thromb Haemost; 2012 Apr; 107(4):648-55. PubMed ID: 22274761
[TBL] [Abstract][Full Text] [Related]
19. Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro.
Muzard J; Bouabdelli M; Zahid M; Ollivier V; Lacapère JJ; Jandrot-Perrus M; Billiald P
FEBS J; 2009 Aug; 276(15):4207-22. PubMed ID: 19558491
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein VI - novel target in antiplatelet medication.
Borst O; Gawaz M
Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
